Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier organic anion transporter family member 1B3 (SLCO1B3), commonly known as OATP1B3, is a key sodium-independent uptake transporter predominantly expressed on the basolateral (sinusoidal) membrane of human hepatocytes. It plays a critical physiological role in the hepatic clearance of endogenous compounds, including bilirubin, bile acids, thyroid hormones, and conjugated steroids, thereby contributing to systemic detoxification. Beyond its physiological substrates, OATP1B3 is highly clinically relevant as it mediates the hepatic uptake of numerous widely prescribed drugs, such as statins, angiotensin II receptor antagonists (e.g., telmisartan), and various chemotherapeutic agents (e.g., paclitaxel and docetaxel). Consequently, inhibition of OATP1B3 by co-administered drugs is a major driver of clinically significant drug-drug interactions, potentially leading to severe toxicities like statin-induced rhabdomyolysis. Additionally, genetic mutations in SLCO1B3, particularly when combined with mutations in SLCO1B1, cause Rotor syndrome, a hereditary form of hyperbilirubinemia. In oncology, an alternative splice variant known as cancer-type OATP1B3 (Ct-OATP1B3) is aberrantly expressed in various solid tumors, where it localizes to lysosomes and contributes to multidrug resistance by sequestering therapeutic agents.
OATP1B3 primarily functions as a sodium-independent, facilitated-diffusion uptake transporter that imports substrates from the sinusoidal blood into hepatocytes for hepatic clearance. Drugs can act as substrates, utilizing this transport mechanism for hepatic elimination, or as inhibitors, blocking the transporter and preventing the uptake of other co-administered drugs. In cancer cells, an intracellularly localized splice variant (Ct-OATP1B3) can sequester drugs into lysosomes, reducing their cytoplasmic concentration and mediating drug resistance.
16 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier organic anion transporter family member 1B3 (OATP1B3).